Coronavirus (COVID-19)

COVID-19 Monoclonal Antibody Infusion Centers for Adult Patients

The US FDA recently granted emergency use authorization (EUA) for select monoclonal antibody therapies for use as post-exposure prophylaxis (prevention) of COVID-19 after known exposure to the virus. Studies have shown that these antibodies may reduce the risk of symptomatic infection after exposure to the virus in high-risk patients. The State of Rhode Island has received a limited supply of these medications for use, and the available inventory has been divided among hospital systems across the state.

These monoclonal antibodies will be administered as a series of 4 subcutaneous injections delivered in the outpatient setting for those high-risk individuals who have had an exposure to COVID-19. A negative COVID swab will be required prior to scheduling. Patients should be referred by their primary care provider or urgent care provider to the Infectious Diseases (ID) Center using the referral form below. Eligible patients must be asymptomatic, and at high risk for hospitalization. Eligible patients will be evaluated by the ID clinical team for eligibility and a risk assessment.

If you meet the criteria below and are interested in this treatment, please speak with your primary care or urgent care provider about a referral. 

Information for Referring Providers

Hours of Service

Referral hours of operation are Monday through Friday, 8 a.m. to 4:30 p.m.

Eligibility Criteria

Patients must meet the criteria as defined in the EUA:

  1. Patient is asymptomatic with a negative COVID-19 test since exposure 
  2. Vaccination Status (one of the following required):
    a. Patient is not fully vaccinated,
    b. Patient is not expected to mount an adequate immune response to complete COVID-19 vaccination
    • COVID-19 Exposure Criteria (one of the following required):
      a. Patient has been exposed to an individual infected with COVID-19 consistent with close contact criteria per CDC AND time from initial exposure ≤ 7 days,
      b. Patient is at high risk of exposure to an individual infected with COVID-19 because of occurrence in other individuals in the same institutional setting (e.g., nursing homes, prisons)
    • Patient is at high risk for progressing to severe COVID-19. For information on medical conditions and factors associated with increased risk for progression to severe COVID, see the CDC website.
    • Referring provider or provider’s designee has reviewed the FDA Fact Sheet for Patients/Caregivers with the patient/caregiver

    Limitations of Authorized Use

    • Post-exposure prophylaxis with monoclonal antibody therapy is not a substitute for vaccination against COVID-19.
    • Monoclonal antibody therapies are not authorized for pre-exposure prophylaxis for prevention of COVID-19.

    Information to Review with Eligible Patients

    If a patient is eligible and you would like to refer them, please review the EUA fact sheet below with the patient and ensure the patient agrees to treatment. Final determination of which monoclonal antibody the patient receives will be determined by available inventory or will be at the discretion of the ID clinical team.

    How to Refer a Patient

    Please review the referring provider criteria (above), then fill out the referral form and fax it to Lifespan at 401-793-7659.